Delivery of hydrophobic active agent particles

Patent metadata

Field	Value
Publication number	US-12083249-B2
Application number	US-202218084247-A
Country	US
Kind code	B2
Filing date	Dec 19, 2022
Priority date	May 20, 2011
Publication date	Sep 10, 2024
Grant date	Sep 10, 2024

Abstract

Embodiments of the invention include drug delivery coatings and devices including the same. In an embodiment, the invention includes a drug delivery coating including a polymeric layer. The polymeric layer can include a hydrophilic outer surface. The coating can also include a matrix contacting the hydrophilic outer surface. The matrix can include a particulate hydrophobic therapeutic agent and a cationic agent. The polymeric layer can further include a hydrophilic polymer having pendent photoreactive groups and a photo-crosslinker including two aryl ketone functionalities. Other embodiments are also included herein.

First claim

The invention claimed is:

1. A drug delivery coating comprising
a base polymeric layer, the base polymeric layer comprising a hydrophilic surface;
a therapeutic agent layer forming an exterior surface of the drug delivery coating, the therapeutic agent layer contacting the hydrophilic surface of the base polymeric layer and having a composition different than the base polymeric layer, the therapeutic agent layer comprising
a hydrophobic therapeutic agent comprising rapamycin or a rapamycin analogue; and
a cationic agent;
wherein a ratio (wt./wt.) of particulate hydrophobic therapeutic agent to the cationic agent is about 99.9/0.1 to 90/10.

2. The drug delivery coating of claim 1 , wherein the ratio (wt./wt.) of hydrophobic therapeutic agent to the cationic agent is about 99.9/0.1 to 95/5.

3. The drug delivery coating of claim 1 , wherein the ratio (wt./wt.) of hydrophobic therapeutic agent to the cationic agent is about 99.9/0.1 to 98/2.

4. The drug delivery coating of claim 1 , wherein the ratio (wt./wt.) of hydrophobic therapeutic agent to the cationic agent is about 99.9/0.1 to 99/1.

5. The drug delivery coating of claim 1 , the cationic agent comprising a polyethyleneimine (PEI) homopolymer or copolymer.

6. The drug delivery coating of claim 5 , the copolymer comprising a PEG block.

7. The drug delivery coating of claim 5 , the copolymer selected from the group consisting of PEG-PEI and PLGA-PEI.

8. The drug delivery coating of claim 1 , the base polymeric layer further comprising a photo-crosslinker comprising at least two aryl ketone functionalities.

9. The drug delivery coating of claim 8 , wherein the photo-crosslinker is chosen from ethylenebis(4-benzoylbenzyldimethylammonium) dibromide and bis(4-benzoyl)phosphate sodium salt.

10. The drug delivery coating of claim 1 , wherein the base polymeric layer comprises a hydrophilic polymer having pendent photoreactive groups.

11. The drug delivery coating of claim 10 , the hydrophilic polymer having pendent photoreactive groups comprising a photo-polyacrylamide.

12. The drug delivery coating of claim 11 , wherein the photo-polyacrylamide is chosen from poly(N-3-aminopropyl)methacrylamide-co-N-(3-(4-benzoylbenzamido)propyl)methacrylamide; poly(acrylamide-co-N-(3-(4-benzoylbenzamido)propyl)methacylamide), poly(acrylamide-co-maleic-6-aminocaproic acid-N-oxysuccinimide-co-N-(3-(4-benzoylbenzamido)propyl)methacrylamide) and poly(acrylamide-co-(3-(4-benzoylbenzamido)propyl)methacrylamide)-co-glycidylmethacrylate.

13. The drug delivery coating of claim 11 , wherein the photo-polyacrylamide is poly(N-3-aminopropyl)methacrylamide-co-N-(3-(4-benzoylbenzamido)propyl) methacrylamide.

14. The drug delivery coating of claim 11 , wherein the photo-polyacrylamide is poly(N-3-aminopropyl)methacrylamide-co-N-(3-(4-benzoylbenzamido)propyl)methacrylamide and the photo crosslinker is ethylenebis(4-benzoylbenzyldimethylammonium) dibromide.

Assignees

• Surmodics Inc

Inventors

• Slager Joram
• Heyer Toni M
• Babcock David E

Classifications

• C12N2320/32

  Special delivery means, e.g. tissue-specific · CPC title

• C12N2310/14

  interfering nucleic acids [NA] · CPC title

• C12N15/113

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• A61M2025/105

  having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes · CPC title

• A61M25/10

  Balloon catheters ({A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02;} inflatable balloons for placing stents or stent-grafts A61F2/958 {; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00}) · CPC title